A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin. Published by the Journal of the American Medical Association (JAMA Psychiatry,) the small pilot study’s findings suggest Safe of one 25mg dose of the biotech’s synthetic psilocybin COMP360 paired with psychotherapy for treating the mentioned mental health condition, a “treatment-resistant cyclical mood disorder” commonly associated with debilitating and difficult-t…
